Business · 21/04/2025Updated: 10/17/2026 · 1 min read
FDA Approves TREMFYA (guselkumab) Product Under Priority Review Voucher
Summary
The FDA has approved a product redeeming a priority review voucher for TREMFYA (guselkumab), a rare pediatric disease treatment, following a review of its supplemental application submitted on an expedited basis.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →